AR106956A1 - Cepas de virus sincitial respiratorio recombinante con mutaciones en el marco de lectura abierto (orf) m2-2 que proporcionan un rango de fenotipos de atenuación - Google Patents
Cepas de virus sincitial respiratorio recombinante con mutaciones en el marco de lectura abierto (orf) m2-2 que proporcionan un rango de fenotipos de atenuaciónInfo
- Publication number
- AR106956A1 AR106956A1 ARP160103793A ARP160103793A AR106956A1 AR 106956 A1 AR106956 A1 AR 106956A1 AR P160103793 A ARP160103793 A AR P160103793A AR P160103793 A ARP160103793 A AR P160103793A AR 106956 A1 AR106956 A1 AR 106956A1
- Authority
- AR
- Argentina
- Prior art keywords
- mutations
- open reading
- viruses
- orf
- phenotypes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18521—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18561—Methods of inactivation or attenuation
- C12N2760/18562—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
En la presente se proporcionan virus sincitiales respiratorios (VSR) que tienen un fenotipo atenuado que contiene mutaciones en el marco de lectura abierto M2-2 que interfieren con la expresión de la proteína M2-2. Las mutaciones M2-2 pueden estar presentes en combinación con mutaciones en otro loci. Usando los métodos descriptos en la presente, se proporcionan combinaciones de mutaciones para lograr niveles deseados de atenuación. Las cepas del VSR recombinante descriptas en la presente son adecuadas para usar como vacunas vivas atenuadas contra el VSR. También se proporcionan secuencias de polinucleótidos de los virus descriptos, como así también métodos para producir y usar los virus.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562266199P | 2015-12-11 | 2015-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR106956A1 true AR106956A1 (es) | 2018-03-07 |
Family
ID=57714677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103793A AR106956A1 (es) | 2015-12-11 | 2016-12-12 | Cepas de virus sincitial respiratorio recombinante con mutaciones en el marco de lectura abierto (orf) m2-2 que proporcionan un rango de fenotipos de atenuación |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10655109B2 (es) |
| EP (1) | EP3386539A1 (es) |
| JP (2) | JP7079197B2 (es) |
| KR (2) | KR102854980B1 (es) |
| CN (1) | CN109310752B (es) |
| AR (1) | AR106956A1 (es) |
| AU (1) | AU2016366771B2 (es) |
| CA (1) | CA3007408A1 (es) |
| WO (1) | WO2017100759A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11273214B2 (en) * | 2017-05-29 | 2022-03-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Recombinant chimeric bovine/human parainfluenza virus 3 expressing RSV G and its use |
| JP2023529836A (ja) * | 2020-06-05 | 2023-07-12 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 生弱毒化呼吸器合胞体ウイルス |
| TW202535439A (zh) | 2023-11-17 | 2025-09-16 | 美商賽諾菲巴斯德公司 | 海藻糖疫苗調配物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3224404A1 (de) | 1982-06-30 | 1984-01-05 | LuK Lamellen und Kupplungsbau GmbH, 7580 Bühl | Reibungskupplung sowie verfahren zu deren montage |
| US7465574B2 (en) | 1994-09-30 | 2008-12-16 | Medimmune, Llc | Recombinant RSV virus expression systems and vaccines |
| US6264957B1 (en) | 1995-09-27 | 2001-07-24 | The United States Of America As Represented By The Department Of Health And Human Services | Product of infectious respiratory syncytial virus from cloned nucleotide sequences |
| US6713066B1 (en) | 1996-07-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2 |
| US20040005542A1 (en) * | 2001-06-22 | 2004-01-08 | Krempl Christine D | Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes |
| JP4268407B2 (ja) | 2000-11-28 | 2009-05-27 | アヴィロン,インコーポレーテッド | 組換えrsvウイルス発現系およびワクチン |
| DE10118446A1 (de) | 2001-04-12 | 2002-10-17 | Thomas Hartung | Prüfverfahren zur Untersuchung fließfähiger Medien auf Gehalte an mikrobiellen Toxinen |
| PT3511015T (pt) | 2012-04-13 | 2021-04-05 | Us Health | Vacina viva e atenuada e geneticamente estável contra o vírus sincicial respiratório e a sua produção |
| US20160228536A1 (en) * | 2013-09-18 | 2016-08-11 | Medimmune, Llc | Recombinant respiratory syncytial virus (rsv) and vaccines |
| US10947512B2 (en) | 2015-08-14 | 2021-03-16 | Research Institute At Nationwide Children's Hospital | Respiratory syncytial virus having altered NS1 protein function and related materials and methods |
-
2016
- 2016-12-12 KR KR1020187019759A patent/KR102854980B1/ko active Active
- 2016-12-12 AU AU2016366771A patent/AU2016366771B2/en active Active
- 2016-12-12 EP EP16822321.2A patent/EP3386539A1/en active Pending
- 2016-12-12 JP JP2018530548A patent/JP7079197B2/ja active Active
- 2016-12-12 KR KR1020257029082A patent/KR20250134719A/ko active Pending
- 2016-12-12 US US16/061,314 patent/US10655109B2/en active Active
- 2016-12-12 WO PCT/US2016/066146 patent/WO2017100759A1/en not_active Ceased
- 2016-12-12 CA CA3007408A patent/CA3007408A1/en active Pending
- 2016-12-12 AR ARP160103793A patent/AR106956A1/es unknown
- 2016-12-12 CN CN201680081646.4A patent/CN109310752B/zh active Active
-
2020
- 2020-05-18 US US16/877,277 patent/US11332721B2/en active Active
-
2022
- 2022-03-01 JP JP2022030778A patent/JP7357709B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7357709B2 (ja) | 2023-10-06 |
| JP7079197B2 (ja) | 2022-06-01 |
| US11332721B2 (en) | 2022-05-17 |
| US20190040365A1 (en) | 2019-02-07 |
| US20200283740A1 (en) | 2020-09-10 |
| WO2017100759A1 (en) | 2017-06-15 |
| KR20250134719A (ko) | 2025-09-11 |
| EP3386539A1 (en) | 2018-10-17 |
| KR102854980B1 (ko) | 2025-09-03 |
| RU2018125246A3 (es) | 2020-05-25 |
| RU2018125246A (ru) | 2020-01-15 |
| CN109310752A (zh) | 2019-02-05 |
| BR112018011674A2 (pt) | 2018-12-04 |
| CA3007408A1 (en) | 2017-06-15 |
| JP2022088376A (ja) | 2022-06-14 |
| US10655109B2 (en) | 2020-05-19 |
| KR20180085803A (ko) | 2018-07-27 |
| AU2016366771B2 (en) | 2022-04-07 |
| JP2018536428A (ja) | 2018-12-13 |
| CN109310752B (zh) | 2022-12-16 |
| AU2016366771A1 (en) | 2018-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018006706A2 (es) | Virus mutados, método de preparación y uso de los mismos | |
| CO2018001534A2 (es) | Una composicion de vacuna arboviral | |
| EP4218807A3 (en) | Zika virus vaccine | |
| BR112018008102A2 (pt) | vacina de vírus sincicial respiratório | |
| MX2018009917A (es) | Vacuna contra el virus del zika. | |
| MX2020005187A (es) | Compuestos y composiciones farmaceuticas antivirales, asi como metodos de uso de los mismos. | |
| MX2016011055A (es) | Nuevo polisacarido y usos del mismo. | |
| MX382425B (es) | Imitadores de mir-29 y usos de los mismos | |
| CO2018003451A2 (es) | Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue | |
| MX2019005136A (es) | Vacuna contra el parvovirus porcino y el virus del sindrome respiratorio reproductivo porcino y metodos de produccion de esta. | |
| ECSP11011033A (es) | Virus sincitial respiratorio vivo atenuado | |
| MX387421B (es) | Producción de virus en huevos aviares. | |
| PH12016500465A1 (en) | Deoxynojirimycin derivatives and methods of their using | |
| CO2018010874A2 (es) | Vacuna de virus de zika atenuado vivo | |
| MX2018006373A (es) | Produccion de virus en cultivos celulares. | |
| MX2017005687A (es) | Metodos para usar formulaciones para vacuna con microagujas para elicitar en animales inmunidad protectora contra virus de la rabia. | |
| CL2019002313A1 (es) | Combinación de cotinina y antioxidante para la resistencia al tratamiento de la depresión y corrección del déficit funcional de los astrocitos inducido por la depresión y otras afecciones neuropatológicas. | |
| ECSP20007842A (es) | Composiciones y métodos para formulaciones de alfavirus vivos atenuados | |
| AR106956A1 (es) | Cepas de virus sincitial respiratorio recombinante con mutaciones en el marco de lectura abierto (orf) m2-2 que proporcionan un rango de fenotipos de atenuación | |
| CL2017001722A1 (es) | Un método de activación de bacterias ácido lácticas | |
| CL2017001595A1 (es) | Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas | |
| BR112017004452A2 (pt) | vírus atenuado, arbovírus atenuado, seus usos, composição de vacina, método de produção de um genoma de vírus atenuado, método de produção de um arbovírus atenuado e genoma de arbovírus atenuado | |
| AR099680A1 (es) | Muteínas mejoradas de factor viii de coagulación | |
| MX394998B (es) | Virus de vacuna del sindrome respiratorio y reproductivo porcino. | |
| CL2018001782A1 (es) | Metodos y composiciones para el tratamiento del sindrome de hunter. |